Fig. 7.

Two-chain urokinase with Ser¹⁹⁵Ala substitution (S195A-tcuPA; 0.5 mg/kg) does not improve the outcomes of intrapleural fibrinolytic therapy (IPFT) with prourokinase (scuPA; 0.25 mg/kg). IPFT outcomes [expressed by gross lung injury score (GLIS; 25, 48)] in the treatment of tetracycline (TCN)-induced pleural injury with (from left to right) 0.5 mg/kg S195A-tcuPA alone (■; n = 3), S195A-tcuPA (0.5 mg/kg) and 0.25 mg/kg scuPA (●; n = 5), vehicle control (PBS; □; n = 3), and scuPA (0.25 mg/kg) alone (○; n = 5) are given. IPFT was considered successful with a GLIS ≤ 10. The data are presented as a box plot (showing interquartile ranges). There was no statistically significant difference between treatments with the scuPA alone and in combination with 0.5 mg/kg of S195A-tcuPA (P > 0.05). The differences in the median values between groups with and without scuPA were statistically significant (P < 0.05).